Dhanuka Agritech has delivered a strong performance for Q4 FY26, beating consensus and broker estimates across all key financial parameters. Despite a soft Rabi season and persistent headwinds in the broader agrochemical sector, the company reported resilient revenue growth and sharp margin expansion. Following the earnings release, Axis Securities maintained its BUY rating on the stock, raising Dhanuka Agritech’s target price to INR 1,650 per share—implying an 41% upside from the CMP of INR 1,172.

Adding to the positive market sentiment, Dhanuka’s board has approved an INR 70-crore share buyback via the tender route.

Dhanuka Agritech Q4 FY26 Performance

Dhanuka Agritech reported a consolidated revenue of INR 483 crore for Q4 FY26, up 9% year-on-year (YoY) and 18% sequentially, outperforming Axis Securities’ estimates by 6%. This growth was primarily driven by strong traction in insecticides and specialty formulations, offsetting weak farmer liquidity and erratic weather patterns.

The operational performance was marked by an EBITDA of INR 125 crore, which significantly outpaced the broker’s estimate of INR 84 crore by 48%. Profit After Tax (PAT) grew 29.5% YoY to INR 98 crore, aided by stronger operational profitability, lower finance costs, and higher other income.

Key Quarterly Financial Metrics

Dhanuka Agritech Buyback Offer

Dhanuka Agritech finalised the structural details of its upcoming buyback offer. The company will buy up to 5,00,000 equity shares via the tender route, aggregating to INR 70 crore.

• Buyback Price: INR 1,400 per equity share
• Current Market Price (CMP): INR 1,182.95
• Buyback Premium: 18.35% over CMP
• Record Date: 29 May 2026

Axis Securities Coverage on Dhanuka Agritech: Key Takeaways

While Axis Securities adjusted its revenue and PAT estimates downward for FY27 and FY28 to account for structural shifting in short-term product mixes, the medium-to-long-term outlook remains structurally sound. Management has laid out clear operational targets for the upcoming fiscal year:

• Bayer Portfolio Scale-Up: A critical growth lever for Dhanuka is its integration of Bayer products. The company clocked ~INR 27 crore from domestic sales of these products in FY26 and projects a steep increase to approximately INR 200 crore in FY27. Export channels are expanding, with distributors already appointed in 5 countries and advanced talks underway in 10 more.
• Biologicals Segment Rebound: After regulatory hurdles caused biological revenues to drop from INR 110 crore to INR 70 crore in FY26, management anticipates a sharp recovery to over INR 130 crore in FY27, supported by three new product launches scheduled for June.
• Dahej Plant Turnaround: The Dahej facility operated at an EBITDA loss of INR 13 crore on a revenue of INR 50 crore in FY26. Management targets a 50% revenue scale-up to INR 75 crore in FY27, driven by domestic bifenthrin demand and new international registrations, aiming to turn the plant accretive over the next two years.
• Pricing Countermeasures: To cushion a 3% to 5% aggregate rise in raw material costs, Dhanuka implemented a ~2% price hike in Q1 and intends to execute an additional 3% to 4% hike entering Q2 to shield its gross margins.

Dhanuka Agritech Valuation and Outlook

Despite immediate sector challenges—including global supply chain volatility and unpredictable monsoon distribution—Dhanuka’s shift toward high-margin, differentiated 9(3) proprietary molecules (targeted to stay at 25–26% of overall revenue) offers strong margin protection.

The brokerage has valued the company at 18x FY28E earnings, arriving at its target price of INR 1,650 per share. Dhanuka Agritech share price is at around ~INR 1,172 per share, implying a ~41% upside.

Dhanuka’s asset-light business model, reinforced by international expansions into Brazil and Europe for brand registrations, insulates it from the risks of heavy R&D expenditure while sustaining a premium product pipeline. The financial outperformance this quarter confirms operational flexibility in a weak demand environment.

Rajat Bhati has a strong technical background and 5 years of experience in the stock market. He focuses on equity research, technical analysis, IPO valuations, and risk management, helping investors make clearer, data-backed decisions. Today, he works full-time to educate people about the opportunities in IPO market.